natgillin/translations-raw huggingface dataset:
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1 wherein said receptacle (100; 200; 400; 500) is provided with a handle for bringing and positioning the outlet (106; 506) of the receptacle (100; 200; 400; 500) in dispensing relation vis-à-vis the mouth of the user. 
Spremnik (100; 200; 400; 500), namijenjen držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, gdje navedeni spremnik (100; 200; 400; 500) ima ručku za dovođenje i stavljanje izlaza (106; 506) spremnika (100; 200; 400; 500) u položaj za izdavanje nasuprot korisnikovih usta.
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1, wherein said sealing closure (112; 212; 412; 512) is maintained in its closed position by interengagement with a frame (114) provided inside said outlet (106; 506). 
Spremnik (100; 200; 400; 500), namijenjen držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, gdje se navedeni hermetički zatvarač (112; 212; 412; 512) drži u svom zatvorenom položaju međudjelovanjem s okvirom (114) koji se nalazi unutar navedenog izlaza (106; 506).
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1 wherein said displaceable sealing closure (112; 212; 412; 512) is formed from a plurality of flexible filaments. 
Spremnik (100; 200; 400; 500), namijenjen držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, gdje je navedeni odvojivi hermetički zatvarač (112; 212; 412; 512) načinjen od više fleksibilnih vlakana.
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1 wherein said outlet is releasably connected to said receptacle (100; 200; 400; 500), optionally wherein said releasable outlet (106; 506) is disposable and replaceable. 
Spremnik (100; 200; 400; 500), namijenjen držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, gdje je navedeni izlaz odvojivo povezan s navedenim spremnikom (100; 200; 400; 500), gdje navedeni odvojivi izlaz (106; 506) može biti jednokratan i zamjenjiv.
A substituted indole derivative of Formula (I), wherein: 
Supstituirani derivat indola formule (I), pri čemu:
represents hydrogen, bromine, or methoxy; 
predstavlja vodik, brom ili metoksi;
represents hydrogen, halogen, methyl, hydroxy, methoxy, benzyloxy, cyano, or amido; 
predstavlja vodik, halogen, metil, hidroksi, metoksi, benziloksi, cijano ili amido;
represents hydrogen or bromine; 
predstavlja vodik ili brom;
represents hydrogen, fluorine, or methyl; 
predstavlja vodik, fluor ili metil;
The pharmaceutical composition according to claim 8 or 9, comprising additional 5-HT7-active components selected from the group comprising aripiprazole, amisulpride, chlorpromazine, clozapine, risperidone, ziprasidone, fluoxetine, 5-CT, 5-methoxytryptamine, 8-OH-DPAT, aripiprazole, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7, and Nω -methylserotonin. 
Farmaceutski pripravak za uporabu prema zahtjevu 5 ili 6, naznačen time što sadrži dodatne 5-HT7- aktivne komponente odabrane iz skupine koja sadrži aripiprazol, amisulprid, klorpromazin, klozapin, risperidon, ziprasidon, fluoksetin, 5-CT, 5-metoksitriptamin, 8 -OH-DPAT, aripiprazol, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7 i Nω-metilserotonin.
A container according to claim 1, wherein the base and the continuous side wall are clear. 
Posuda prema patentnom zahtjevu 1, pri čemu su osnova i kontinuirani bočni zid prozirni.
A container according to claim 2, wherein the base and the continuous side wall consist essentially of recycled PET. 
Posuda prema patentnom zahtjevu 2, pri čemu se osnova i kontinuirani bočni zid sastoje u osnovi od recikliranog PET-a.
A container according to claim 1, 2 or 3, wherein the adhesive is an adhesive based on a polymeric substrate or a polyethylene(PE) or PE co-polymer based material. 
Posuda prema patentnim zahtjevima 1, 2 ili 3, pri čemu, lepak je lepak na bazi polimernog supstrata ili polietilena (PE) ili materijala na bazi PE kopolimera.
A container according to any preceding claim, wherein the thickness of the layer of adhesive is from 20 µm to 100 µm, preferably 50 µm. 
Posuda prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je debljina sloja ljepila od 20 µm do 100 µm, a poželjno 50 µm.
A container according to claim 10, wherein the atmosphere within the sealed container has been modified or controlled. 
Posuda prema patentnom zahtjevu 10, pri čemu je atmosfera unutar pričvršćene posude modificirana ili kontrolirana.
A container according to any preceding claim, wherein the thickness of the lidding film is from 20 µm to 60 µm. 
Posuda prema bilo kojem od patentnih zahtjeva 10 do 13, pri čemu je debljina tankog filma od 20 µm do 60 µm.
providing a multi-layer lidding film comprising a seal layer and the seal layer comprises polypropylene (PP) and/or PE. 
pružanje višeslojnog tankog filma koji sadrži sloj za pričvršćivanje i sloj za pričvršćivanje sadrži polipropilen (PP) i/ili PE.
applying pressure to the peripheral flange to seal the lidding film to the container. 
primjenu pritiska na obod kako bi se izvršilo zatvaranje tankog filma na posudu.
A process according to claim 21, wherein pressure is applied to the peripheral flange at a pressure of from 206.84 KPa to 1241.06 KPa (30 psi to 180 psi) for a period of time of from 0.5 seconds to 5 seconds, preferably 758.42 KPa (110) psi for 1 second. 
Postupak prema patentnom zahtjevu 21, pri čemu se pritisak primjenjuje na obod pod tlakom od 206,84 KPa do 1241,06 KPa (30 psi do 180 psi) u periodu od 0,5 sekundi do 5 sekundi, poželjno 758,42 KPa (110 psi) u trajanju 1 sekunda.
A process according to claim 23, wherein heat is applied to the peripheral flange at a temperature of from 105 °C to 170 °C, preferably at a temperature of 150 °C. 
Postupak prema patentnom zahtjevu 23, pri čemu se toplina primjenjuje na obod pri temperaturi od 105°C do 170°C, a poželjno pri temperaturi od 150°C.
A process according to any of claims 21 to 24, wherein a sealing shoe matching the shape of the peripheral flange is used to seal the lidding film to the sealable container. 
Postupak prema bilo kojem od patentnih zahtjeva 21 do 24, pri čemu se koristi kalup za zatvaranje koji odgovara obliku oboda, za zatvaranje tankog filma na posudu pogodnu za zatvaranje.
R″ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle; 
R" je izabran, nezavisno za svaki slučaj, od H, metila, etila, propila, butila, -C(O)-metila i -C(O)-etila, ili R’ i R" uzeti zajedno sa azotom za koji su vezani mogu formirati 4-6 –člani heterociklus;
The compound of claim 1, wherein R10 is selected from the group consisting of H, methyl and F. 
Spoj prema bilo kojem od patentnih zahtjeva 1-2, naznačen time što R10 je izabran iz grupe koja se sastoji od H, metila i F.
A method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound of claim 1, and one or more other HBV agent each selected from the group consisting of HBV capsid assembly promoters, HBF viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7/9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists. 
Prvi spoj izabran iz bilo kojeg od patentnih zahtjeva 1-4, i jedan ili više drugih HBV sredstava od kojih je svaki izabran iz grupe koja se sastoji od promotora sklapanja HBV kapsida, nukleozida koji interferiraju sa polimerazom HBF virusa, inhibitora ulaska virusa, inhibitora izlučivanja HBsAg, sredstava koja prekidaju formiranje nukleokapsida, inhibitora formiranja cccDNK, antivirusnog mutanta proteina jezgre, trans-tijela usmjerenih ka HBc, RNKi koje ciljno djeluju na RNK HBV, imunostimulanata, agonista TLR-7/9, inhibitora ciklofilina, HBV cjepiva, mimetika SMAC, epigenetičkih modulatora, inhibitora kinaze i agonista STING za uporabu u liječenju infekcije hepatitisa B.
comprising: (a-1) reacting compound I-1: in the presence of a solvent, an oxidizing agent, and Catalyst A to form an aldehyde in situ, followed by a condensation in the presence of NaCN or KCN and ammonium chloride and a protective reagent to produce compound I-2: 
koji nadalje sadrži: (a-1) reakciju spoja I-1: u prisutnosti otapala, oksidacijskog sredstva, i Katalizatora A da se dobije aldehid in situ, nakon čega slijedi kondenzacija u prisutnosti X-CN i amonijevog klorida i zaštitnog reagensa da se dobije spoj 1-2: (b-1) reakciju spoja 1-2 u prisutnosti fenil Grignardovog reagensa da se dobije spoj 1-3: pri čemu je X odabran od Na i K.
The process of claim 3, wherein in step (a-1): the solvent is selected from the group consisting of THF, MTBE, CH2Cl2, MeCN, EtOAc, i-PrOAc, Me-THF, hexane, heptane, DMAc, DMF, methyl cyclopentyl ether, toluene and combinations thereof; the oxidizing agent is selected from the group consisting of NaOCl, NaClO2, PhI(OAc)2, hydrogen peroxide; pyridine sulfur trioxide/Et3N/DMSO and a Moffatt variant, PCC, DCC, a Swern oxidation or its variants, and TPAP/NMO; and Catalyst A is TEMPO or a TEMPO analogue. 
Postupak prema patentnom zahtjevu 3, naznačen time što je u koraku (a-1): otapalo odabrano iz skupa koji sadrži THF, MTBE, CH2Cl2, MeCN, EtOAc, i-PrOAc, Me-THF, heksan, heptan, DMAc, DMF, metil ciklopentil eter, toluen i njihove kombinacije; oksidacijsko sredstvo je odabrano iz skupa koji sadrži NaOCl, NaClO2, PhI(OAc)2, vodikov peroksid, piridin sulfur trioksid/Et3N/DMSO i Moffatt-ovu varijantu, PCC, DCC, Swern-ovu oksidaciju ili njezine varijante, TPAP/NMO; i katalizator je TEMPO ili TEMPO analog.
The process of claim 3, wherein in step (a-1) compound I-2 can be prepared via a hydrogensulfite adduct. 
Postupak prema patentnom zahtjevu 3, naznačen time što se u koraku (a-1) spoj 1-2 može pripremiti preko hidrogensulfitnog adukta.
The process of claim 2, wherein the KRED enzyme in step (a-2) comprises the amino acid sequence set forth in SEQ NO.1 or an active fragment thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što enzim dinamičke kinetičke redukcije KRED u koraku (a-2) sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO.1 ili njezin aktivni fragment.
The process of claim 2, wherein a cofactor recycling system is present in step (a-2). 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što je sustav recikliranja kofaktora prisutan u koraku (a-2).
The process of claim 2, wherein the reaction in step (a-2) is carried out in a solvent selected from the group consisting of 2-propanol, sec-butanol, iso-butanol, DMSO, DMF, DMAc, NMP, and combinations thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što se reakcija u koraku (a-2) provodi u otapalu koje se bira iz skupine koju čine 2-propanol, sec-butilni alkohol, izo-butanol, DMSO, DMF, DMAc, i NMP, i njihove kombinacije.
The process of claim 2, wherein the reaction in step (b-2) is carried out in the presence of a solvent selected from the group consisting of THF, IPA, MeOH, EtOH, n-PrOH, NMP, DMF, DMAc, MTBE, CH2Cl2, MeCN, Me-THF, methyl cyclopentyl ether, toluene, and combinations thereof. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što se reakcija u koraku (b-2) provodi u prisutnosti otapala koje se bira iz skupine koju čine THF, IPA, MeOH, EtOH, n-PrOH, NMP, DMF, DMAc, MTBE, CH2Cl2, MeCN, Me-THF, metil ciklopentil eter, i toluen, te njihove kombinacije.
The process of claim 2, wherein compound I-5(b) salt reacts in step (c-2) with a base selected from the group consisting of Et3N, i-Pr2NEt, i-Pr2NH, pyridine, lutidine, N-methyl morphine, t-BuOK, t-BuONa, t-BuOLi, NaH, NaHMDS, LiHMDS, and KHMDS to produce compound I-6-1 through an intramolecular cyclization reaction. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što sol spoja I-5(b) reagira u koraku (c-2) s bazom odabranom iz skupine koja se sastoji od Et3N, i-Pr2NEt, i-Pr2NH, piridin, lutidin, N-metil morfin, t-BuOK, t-BuONa, t-BuOLi, NaH, NaHMDS, LiHMDS, i KHMDS da se reakcijom intramolekularne ciklizacije dobije spoj 1-6-1.
The window according to any preceding claim, wherein at least one hinge comprises a first part having an approximate quadrant shape (176) and a second part having a rectilinear portion (172), wherein the parts are pivoted to one another and the first part is arrangeable on the upper or lower surface of the hinge side of the first casement and the second part is movable along the respective channel. 
Prozor prema bilo kojem od prethodnih zahtjeva, naznačen time da barem jedna šarka obuhvaća prvi dio koji ima otprilike kvadrantan oblik (176) i drugi dio koji ima pravocrtni dio (172), pri čemu su dijelovi okretni jedan prema drugome i prvi dio se može namjestiti na gornju ili donju površinu strane sa šarkama prvog krila i drugi dio je pokretan uzduž odgovarajućeg kanala.
The window according to claim 7, wherein the landing strip comprises a side wall (92) to reduce the width of the respective channel such that it is approximately equal to the width of the second part (172). 
Prozor prema zahtjevu 7, naznačen time da podestna letvica obuhvaća bočni zid (92) za smanjenje širine odgovarajućeg kanala na način da je otprilike jednak širini drugog dijela (172).
Oral pharmaceutical composition comprising coated particles of a complex of at least one active agent with an ion-exchange resin, wherein said particles are coated with a bioadhesive coating layer comprising at least one bioadhesive material and further comprise an enteric coating layer which is placed over the bioadhesive layer and comprises at least one enteric coating material, wherein the active agent is selected from the group consisting of levodopa, carbidopa, benserazide, entacapone and mixtures thereof, alendronate, olanzapine, risperidone and ropinirole, and wherein the bioadhesive material is selected from the group consisting of optionally crosslinked homopolymers of acrylic acid or an alkylacrylic acid and optionally crosslinked copolymers of acrylic acid or methacrylic acid with a (C10-C30) alkyl acrylate. 
Oralni farmaceutski pripravak, naznačen time,da obuhvaća obložene čestice jednog kompleksa od najmanje jedne djelatne tvari sa smolom ionske izmjene, pri čemu su navedene čestice obložene bioljepljivim obložnim slojem koji sadrži najmanje jedan bioljepljivi materijal i uz to obuhvaća jedan enterički obložni sloj koji se nalazi preko bioljepljivog sloja i koji sadrži najmanje jedan enterički obložni materijal, pri čemu je djelatna tvar odabrana iz skupine koja se sastoji od sljedećih: levodopa, karbidopa, benserazid, entakapon, i njihove mješavine, alendronat, olanzapin, risperidon i ropinirol, i pri čemu je bioljepljivi materijal odabran iz skupine koja se sastoji od opcionalno križno povezanih homopolimera akrilne kiseline ili alkilakrilne kiseline i opcionalno križno povezanih kopolimera akrilne kiseline ili metakrilne kisline s jednim (C10-C30)alkil-akrilatom.
Composition according to any one of claims 2 to 5 comprising at least two groups of coated particles differing in the amount and/or the composition of release modifying material. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time,da obuhvaća najmanje dvije skupine obloženih čestica, koje se razlikuju u količini i/ili sastavu materijala koji modificira oslobađanje.
Composition according to any one of claims 1 to 6, wherein the ion exchange resin is selected from the group consisting of polymers and copolymers of acrylic acid, methacrylic acid and styrene modified with ionic groups, cellulose modified with ionic groups, dextran modified with ionic groups and silica gel modified with ionic groups, wherein said ionic groups are selected from sulfonate groups, tertiary amine groups and quaternary ammonium groups, and preferably is a crosslinked sulfonated copolymer of styrene and divinylbenzene. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time,da je smola ionske izmjene odabrana iz skupine koja se sastoji od polimera i kopolimera akrilne kiseline, metakrilne kiseline i stirena modificiranog ionskim skupinama, celuloze modificirane ionskim skupinama, dekstrana modificiranog ionskim skupinama i silika gela modificiranog ionskim skupinama, pri čemu su navedene ionske skupine odabrane od sulfonatnih skupina, tercijarnih aminskih skupina i kvarternih amonijevih skupina, i poželjno od križno povezanog sulfonatnog kopolimera stirena i divinilbenzena.
Composition according to any one of claims 1 to 7, wherein the average particle size of the particles of the complex of the active agent with the ion-exchange resin is 10 to 3000 µm, particularly 30 to 2000 µm and most preferably 50 to 1000 µm, and/or the average particle size of the coated particles is 20 to 5000 µm, particularly 50 to 4000 µm and most preferably 70 to 3000 µm, and/or the coated particles have a specific gravity in the range from 1.1 to 2.0 and preferably from 1.2 to 1.8, and/or the coated particles exhibit a specific surface area in the range of from 1 to 200 m2/g. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time,da prosječna veličina čestice od čestica u kompleksu djelatne tvari sa smolom ionske izmjene, iznosi 10 do 3000 μm, posebno 30 do 2000 μm i najpoželjnije 50 do 1000 μm, i/ili prosječna veličina čestice od obloženih čestica iznosi 20 do 5000 μm, posebno 50 do 4000 μm i najpoželjnije 70 do 3000 μm, i/ili obložene čestice imaju specifičnu težinu u rasponu od 1,1 do 2,0 i poželjno od 1,2 do 1,8, i/ili obložene čestice posjeduju specifično površinsko područje u rasponu od 1 do 200 m2/g.
Composition according to any one of claims 1 to 8 comprising at least two groups of coated particles comprising different active agents. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time,da obuhvaća najmanje dvije skupine obloženih čestica, koje sadrže različite djelatne tvari.
actuation by the mouth of the user interacting with said outlet (106; 506) causes displacement of said displaceable sealing closure (112; 212; 412; 512) from said closed position, to enable the dispensing of at least one pill from said chamber (104; 204; 404), and characterized in that 
pokretanje usta korisnika u interakciji sa navedenim izlazom (106; 506) izaziva pomicanje navedenog odvojivog hermetičkog zatvarača (112; 212; 412; 512) iz navedenog zatvorenog položaja, kako bi se omogućilo izdavanje najmanje jedne tablete iz navedene komore (104; 204; 404), i naznačen time
displacement of said displaceable sealing closure (112; 212; 412; 512) from said closed position to enable the dispensing of at least one pill from said chamber (104; 204; 404), is actuated by one of the following 
što se pomicanje navedenog odvojivog hermetičkog zatvarača (112; 212; 412; 512) iz navedenog zatvorenog položaja kako bi se omogućilo izdavanje najmanje jedne pilule iz navedene komore (104; 204; 404), pokreće jednim od sljedećih
suction applied to said outlet (106; 506) and said closure (112; 212; 412; 512) by the mouth of the user, 
usisavanjem koje se primjeni na navedeni izlaz (106; 506) i navedeni zatvarač (112; 212; 412; 512) korisnikovim ustima,
inhalation applied to said outlet (106; 506) and said closure (112; 212; 412; 512) by the mouth of the user, and 
udisanjem koji se primjeni na navedeni izlaz (106; 506) i navedeni zatvarač (112; 212; 412; 512) korisnikovim ustima, i
exhalation applied to said outlet (106; 506) and said closure (112; 212; 412; 512) by the mouth of the user. 
izdahom koji se primjeni na navedeni izlaz (106; 506) i navedeni zatvarač (112; 212; 412; 512) korisnikovim ustima.
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 1, wherein displacement of said closure (112; 212; 412; 512) from said closed position, to enable the dispensing of at least one pill from said chamber (104; 204; 404), is actuated by an air pressure differential. 
Spremnik (100; 200; 400; 500), namijenjen držanju i izdavanju čvrstih medicinskih pilula u skladu sa patentnim zahtjevom 1, gdje se pomicanje navedenog zatvarača (112; 212; 412; 512) iz navedenog zatvorenog položaja, kako bi se omogućilo izdavanje najmanje jedne pilule iz navedene komore (104; 204; 404), pokreće razlikom u tlaku zraka.
sensitive elements (S1.1.1), 
osjetljive elemente (S1.1.1),
said electronic circuit (S1.3) comprising: 
navedeni strujni krug (S1.3) sadrži:
circuits (S1.3.1) that integrates contact points (S1.3.1.1), 
krug (S1.3.1) koji integrira kontaktne točke (S1.3.1.1),
the data processing system (S3) determines the value of the flow rate referent to the active combination of circuits (S1.3.1) that make up the electronic circuit (S1.3). 
sustav (S3) za obradu podataka određuje vrijednost brzine toka koja se odnosi na aktivnu kombinaciju kruga (S1.3.1) koji sačinjavaju električni krug (S1.3).
Equipment for controlling, measuring and reporting a physical quantity of a container containing a fluid under pressure according to claim 1 characterized in that the dosing knob (S1.1) is connected via the slots (S1.1.2) to the adjustable mechanical valve (7). 
Oprema za kontroliranje, mjerenje i izvještavanje fizičke veličine posude koja sadrži fluid pod pritiskom prema patentnom zahtjevu 1, okarakterizirana time da dugme (S1.1) za doziranje je povezano preko proreza (S1.1.2) za podesiv mehanički ventil (7).
Method for controlling, measuring and reporting the value of the fluid flow rate determined by the equipment for controlling, measuring and reporting a physical quantity of a container containing a fluid under pressure claimed in the preceding claims characterized in that: 
Metoda za kontroliranje, mjerenje i izvještavanje vrijednosti brzine toka fluida koja je određena pomoću opreme za kontroliranje, mjerenje i izvještavanje fizičke veličine posude koja sadrži fluid pod pritiskom za koju se traži zaštita u prethodnim patentnim zahtjevima okarakterizirana time da:
the user chooses manually the amount of flow that will be released via the dosing knob (S1.1), 
korisnik bira ručno količinu toka koja će se osloboditi putem dugmeta (S1.1) za doziranje,
the activation of the circuit (S1.3.1) is transmitted to the electronic board which incorporates the data processing system (S3), 
aktivacija kruga (S1.3.1) prenosi se do elektronske ploče koja inkorporira sustav (S3) za obradu podataka,
the data processing system (S3) determines the value of the flow rate based on the active combination of circuits (S1.3.1) that make up the electronic circuit (S1.3), 
sustav (S3) za obradu podataka određuje vrijednost brzine toka na osnovu aktivne kombinacije kruga (S1.3.1) koji sačinjavaju električni krug (S1.3),
An apparatus comprising in series: 
Uređaj koji sadrži u seriji:
a first folding means for folding a napkin (100) along a first fold (108); 
prvo sredstvo za savijanje za savijanje ubrusa (100) duž prvog preklopa (108);
wherein said adhesive is of a type that will allow said first and said second adhesive portions to separate and allow said napkin (100) to be adhered to an object. 
pri čemu je navedeno ljepilo vrste koje će omogućiti navedenom prvom i navedenom drugom adhezivnom dijelu da se odvoje i omoguće navedenom ubrusu (100) lijepljenje za objekt.
An apparatus according to claim 1, wherein said adhesive applying means sprays said adhesive onto said first surface (106). 
Uređaj prema zahtjevu 1, gdje nanošenje navedenog ljepila znači raspršivanje navedenog ljepila na navedenu prvu površinu (106).
an apparatus according to claim 1 or claim 2. A napkin manufacturing apparatus according to claim 3, wherein the apparatus is configured such that said adhesive is applied to said sheet material before said sheet material is cut into napkins. 
Uređaj za proizvodnju ubrusa prema zahtjevu 3, pri čemu je uređaj konfiguriran tako da se navedeno ljepilo nanosi na navedeni materijal u listovima prije nego što je navedeni materijal izrezan na ubruse.